Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVH200 is a standardized, freeze-dried inner leaf gel extract of *Aloe barbadensis* Mill. (Aloe vera) developed by Calmino Group AB. The extract is chemically defined, containing primarily aloin and acemannan, and is formulated as an effervescent tablet for oral administration. AVH200 possesses immunosuppressive and anti-inflammatory properties, characterized by its ability to suppress T cell proliferation, reduce the expression of CD25 on CD3+ T cells, and inhibit the secretion of pro-inflammatory cytokines such as interleukin-2 (IL-2), interferon-gamma (IFN-γ), and interleukin-17A (IL-17A). It has been investigated in clinical trials as a potential treatment for irritable bowel syndrome (IBS), aiming to modulate immune activation within the gut mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AVH200.